Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31061623 | 1.00 | NPC1 (1.00) | NPC1MTOR | |
| SCHEMBL29532115 | 1.00 | NPC1 (1.00) | NPC1MTOR | |
| SCHEMBL7004604 | 0.84 | NPC1 (0.73) | NPC1MTOR | |
| SCHEMBL338691 | 0.83 | NPC1 (0.71) | NPC1MTOR | |
| SCHEMBL339136 | 0.81 | NPC1 (0.68) | NPC1MTOR | |
| SCHEMBL25282379 | 0.81 | NPC1 (0.67) | NPC1MTOR | |
| SCHEMBL29411871 | 0.81 | NPC1 (0.67) | NPC1MTOR | |
| SCHEMBL340139 | 0.79 | NPC1 (0.65) | NPC1MTOR | |
| SCHEMBL339249 | 0.79 | NPC1 (0.65) | NPC1MTOR | |
| SCHEMBL31237357 | 0.78 | ALDH1A1 (0.65) | NPC1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002348-A1 | QUINOLONE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-01-04 | — | — | US | disclosed |
| EP-4204410-A1 | QUINOLONE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | Council of Scientific & Industrial Research, an Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) (IN) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022044033-A1 | QUINOLONE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860)) (IN) | 2022-03-03 | — | — | WO | disclosed |
| EP-3302488-B1 | NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY | TAIRX INC (TW) | 2020-09-30 | — | — | EP | disclosed |
| EP-3302488-B1 | NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY | TAIRX INC (TW) | 2020-09-30 | — | — | EP | disclosed |
| US-9717721-B2 | Use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry | TAIRX, INC. (TW) | 2017-08-01 | — | — | US | disclosed |
| US-9717721-B2 | Use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry | TAIRX, INC. (TW) | 2017-08-01 | — | — | US | disclosed |
| US-9717721-B2 | Use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry | TAIRX, INC. (TW) | 2017-08-01 | — | — | US | disclosed |
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009519-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | EFFICIENT PHARMA MANAGEMENT CORP. (TW) | 2012-01-19 | — | — | WO | disclosed |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2010-07-01 | — | — | US | disclosed |
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2010-07-01 | — | — | US | disclosed |
| WO-2008070176-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | CHINA MEDICAL UNIVERSITY (TW) | 2008-06-12 | — | — | WO | disclosed |
| EP-1322615-A2 | FLUORINATED QUINOLONES AS ANTIMITOTIC AND ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6569870-B1 | Anticarcinogenic agents for breast and ovarian cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-05-27 | — | — | US | disclosed |
| WO-2002026730-A2 | FLUORINATED QUINOLONES AS ANTIMITOTIC AND ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168064-A1 | NOVEL HYDROPHILIC DERIVATIVES OF 2-ARYL-4-QUINOLONES AS ANTICANCER AGENTS | DHX30, SLC20A2, DDX20 | NPC1 4192/4885MTOR 1578/4885 |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | NPC1 874/4885MTOR 2666/4885 |
| US-20240002348-A1 | QUINOLONE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | SQLE, NQO2, CYP1B1 | NPC1 4642/4885MTOR 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.